Heartbeam Inc(BEAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BEAT Heartbeam Inc

Market Closed 01-09 16:00:00 EST

2.40

+0.04

+1.69%

盘后2.41

+0.01+0.42%

19:49 EST

High2.40	Low2.23	Vol1.45M
Open2.34	D1 Closing2.36	Amplitude7.20%
Mkt Cap82.66M	Tradable Cap59.54M	Total Shares34.44M
T/O3.36M	T/O Rate5.86%	Tradable Shares24.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BEAT","market":"US","secType":"STK","nameCN":"Heartbeam Inc","latestPrice":2.4,"timestamp":1767992400000,"preClose":2.36,"halted":0,"volume":1454269,"hourTrading":{"tag":"盘后","latestPrice":2.41,"preClose":2.4,"latestTime":"19:49 EST","volume":52420,"amount":125788.4804,"timestamp":1768006199935},"delay":0,"floatShares":24806541,"shares":34443563,"eps":-0.657026,"marketStatus":"Market Closed","change":0.04,"latestTime":"01-09 16:00:00 EST","open":2.34,"high":2.4,"low":2.23,"amount":3357624.26568,"amplitude":0.072034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.657026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":2.36,"preHourTrading":{"tag":"盘前","latestPrice":2.35,"preClose":2.36,"latestTime":"09:28 EST","volume":8447,"amount":20043.698777,"timestamp":1767968892013},"postHourTrading":{"tag":"盘后","latestPrice":2.41,"preClose":2.4,"latestTime":"19:49 EST","volume":52420,"amount":125788.4804,"timestamp":1768006199935},"volumeRatio":0.8004695146441599,"impliedVol":0.0501,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BEAT","defaultTab":"news","newsList":[{"id":"2601088504","title":"HeartBeam Inc. to Attend JP Morgan Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601088504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601088504?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614444,"startTime":"0","endTime":"0","summary":"HeartBeam, Inc. will attend the JP Morgan 2026 Annual Healthcare Conference, taking place January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco, CA. The company plans to discuss its upcoming limited U.S. commercial launch and recent FDA clearance for its 12-lead ECG synthesis software.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbvrtnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323591593.USD","LU0320765489.SGD","LU2381873111.SGD","BK4516","IE00B775SV38.USD","IE00BFXG1179.USD","LU0251132253.USD","LU0942090050.USD","SG9999002224.SGD","LU0689472784.USD","BK4588","LU1551013425.SGD","LU1267930490.SGD","LU0149725797.USD","LU0267386448.USD","LU2592432038.USD","LU2211815571.USD","LU0106261372.USD","BK4550","LU1064131342.USD","LU1244550577.SGD","LU0256863811.USD","LU0211326755.USD","LU1244550494.USD","LU0211326839.USD","LU2552382132.HKD","LU1670628061.USD","LU0496365809.HKD","LU2430703095.HKD","BK4504","LU0211327993.USD","IE00BBT3K403.USD","BK4566","LU2746668461.USD","LU1894683264.USD","LU1974910355.USD","LU2417539215.USD","IE000M9KFDE8.USD","LU1244550221.USD","BEAT","LU1280957306.USD","LU1366192091.USD","LU1917777945.USD","LU1496350171.SGD","LU1629891620.HKD","LU1119994496.HKD","LU2462157665.USD","LU0882574139.USD","LU0943347566.SGD","LU1670627923.USD"],"gpt_icon":0},{"id":"2593456266","title":"10% Owner Mark E. Strome Reports Disposal of HeartBeam Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593456266","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593456266?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:31","pubTimestamp":1766446269,"startTime":"0","endTime":"0","summary":"Mark E. Strome, a 10% owner of HeartBeam Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL6RxCQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"10% Owner Mark E. Strome Reports Disposal of HeartBeam Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2590376465","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2590376465","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590376465?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:30","pubTimestamp":1765395031,"startTime":"0","endTime":"0","summary":"HeartBeam  said Wednesday that the US Food and Drug Administration has granted a 510 clearance for its 12-lead electrocardiogram, or ECG, synthesis software for use at home or anywhere to assess arrhythmia.Shares soared 66% as intraday trading volume catapulted to over 218.9 million from a daily average of about 2.3 million.Photronics  shares surged 45% amid heavy trading after the firm reported fiscal Q4 non-GAAP earnings and sales above analysts' estimates on Wednesday.Intraday trading volume advanced to over 13.3 million shares from a daily average of roughly 781,000.UBS adjusted its price target on Designer Brands  to $7 from $4.50 while maintaining its neutral rating for the stock, following the company's Q3 results on Tuesday, in which it reported a surge in adjusted earnings and an improvement in gross margin from a year ago.Shares of Designer Brands jumped 13%, with intraday trading volume at over 4.7 million compared with a daily average of about 880,000.Price: 1.34, Change: +","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BK4094","PLAB","DBI.AU","BK4585","DBI","BK7079","BK4147","BEAT","BK4588"],"gpt_icon":0},{"id":"2590328435","title":"Heartbeam Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590328435?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:22","pubTimestamp":1765390920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 13:22 ET (18:22 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAT"],"gpt_icon":0},{"id":"2590397875","title":"Why Is Micro Cap HeartBeam Stock Surging On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590397875","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590397875?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:27","pubTimestamp":1765384020,"startTime":"0","endTime":"0","summary":"HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac detection technology.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Chest-Pain-Illness-Causing-Heart-Attack-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Chest-Pain-Illness-Causing-Heart-Attack-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/12/49310554/why-is-micro-cap-heartbeam-stock-surging-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/12/49310554/why-is-micro-cap-heartbeam-stock-surging-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BEAT","ECG","BK4082","BK4129"],"gpt_icon":0},{"id":"2590581429","title":"HeartBeam Wins FDA Clearance for At-Home Cable-Free 12-Lead ECG System","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581429?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:00","pubTimestamp":1765368053,"startTime":"0","endTime":"0","summary":"HeartBeam, Inc. has received 510 clearance from the U.S. Food and Drug Administration  for its cable-free synthesized 12-lead electrocardiogram  software designed for at-home arrhythmia assessment. This decision follows a successful appeal of a previous Not Substantially Equivalent  determination. The patented technology enables patients to capture a comprehensive 12-lead ECG from home, with results reviewed by an on-demand, board-certified cardiologist. HeartBeam plans to initiate a limited market launch in early 2026, targeting select concierge and preventive cardiology groups to validate real-world performance before broader commercialization. No other organizations are mentioned as recipients of this regulatory clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4zXRLn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAT","BK4082"],"gpt_icon":0},{"id":"2590581414","title":"Heartbeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead Ecg for at-Home Arrhythmia Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581414?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:00","pubTimestamp":1765368001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA2BFVBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2589358339","title":"Heartbeam Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358339","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358339?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:35","pubTimestamp":1765197300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 07:35 ET (12:35 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2589330094","title":"HC Wainwright Initiates HeartBeam at Buy With $2.50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330094","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330094?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197020,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates HeartBeam at Buy With $2.50 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2587731921","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731921?lang=en_us&edition=fundamental","pubTime":"2025-11-29 01:48","pubTimestamp":1764352135,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  reported Friday it priced a public offering of 80 million shares or pre-funded warrants at $0.75 each, targeting $60 million in gross proceeds.The net proceeds will be used for general corporate purposes, including research, clinical trials, and potential acquisitions or licensing activities.Shares surged 54% as intraday trading volume catapulted to over 155.3 million from a daily average of about 3.9 million.HeartBeam  said late Wednesday it received a \"Not Substantially Equivalent\" decision from the US Food and Drug Administration on its 12-lead ECG synthesis software submission, and said it is actively engaging with the agency on multiple regulatory paths, including potential labeling modifications.The company said its supporting clinical study met its endpoints and believes remaining FDA concerns can be addressed.Shares jumped 24%, with intraday trading volume at over 96.9 million compared with a daily average of about 425,000.Price: 1.63, Change: +0.57, Perc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BEAT","BK4082","KTTA","BK4139"],"gpt_icon":0},{"id":"2587859739","title":"Crude Oil Gains 1%; Tilray Brands Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2587859739","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587859739?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:27","pubTimestamp":1764347270,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/11/49117855/crude-oil-gains-1-tilray-brands-shares-plunge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","BEAT","BK4539","TSYW.SI","SQQQ","BK4547","BK4082","PSQ","LU0348766576.USD","BK4526","BK4139","NVIW.SI","BK4135","DEFT","QID","BK4007",".IXIC","KTTA","TLRY","MNQmain","BK4610","USJW.SI","BK4596","USAW.SI","BK4557","ANPA","BK4144","QLD","LU0348767384.USD","BK4087","NQmain","RUBI"],"gpt_icon":1},{"id":"2586783689","title":"Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2586783689","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586783689?lang=en_us&edition=fundamental","pubTime":"2025-11-28 17:49","pubTimestamp":1764323340,"startTime":"0","endTime":"0","summary":"Shares of Heartbeam Inc  rose sharply in pre-market trading after announcing its regulatory strategy following the Food and Drug Administration’s Not Substantially Equivalent  decision on its 12-lead Electrocardiogram Synthesis Software.The Santa Clara-based medical technology company is pursuing multiple options, including an appeal process or a 510 resubmission, a premarket FDA filing showing the device is equivalent to legally marketed products.Heartbeam shares jumped 43.3% to $0.86 in the pre-market trading session.Here are some other stocks moving in pre-market trading.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/28/Section-Of-A-Financial-Newspaper-Titled-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/28/Section-Of-A-Financial-Newspaper-Titled-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/11/49110264/why-heartbeam-shares-are-trading-higher-by-around-43-here-are-20-stocks-moving-premarket","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/11/49110264/why-heartbeam-shares-are-trading-higher-by-around-43-here-are-20-stocks-moving-premarket","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2586214329","title":"What's Behind HeartBeam's Over 40% After-Hours Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586214329","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586214329?lang=en_us&edition=fundamental","pubTime":"2025-11-27 14:37","pubTimestamp":1764225420,"startTime":"0","endTime":"0","summary":"HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/27/Other-Key-Trades.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/27/Other-Key-Trades.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/49101632/whats-behind-heartbeams-over-40-after-hours-surge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/49101632/whats-behind-heartbeams-over-40-after-hours-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","LU1642822529.SGD","LU0957808578.USD","BK4082","LU2249611893.SGD","LU2506951792.HKD","LU1988902786.USD","LU2264538146.SGD","BK4588","LU0476273544.USD","LU2294711713.HKD","LU1815336760.USD","LU2357125470.USD","LU0823414551.USD","BEAT","LU0823414478.USD","LU0444973449.USD","BK4541","LU1064131342.USD","BK4182","LU0444971666.USD"],"gpt_icon":1},{"id":"2586298326","title":"HeartBeam Pursues FDA Resolution After 12-Lead ECG Software Receives NSE Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298326","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586298326?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:32","pubTimestamp":1764192732,"startTime":"0","endTime":"0","summary":"HeartBeam Inc. announced it has received a Not Substantially Equivalent  decision from the FDA on its 510 submission for its 12-lead ECG Synthesis Software. The company is actively engaging with the FDA to address concerns and is pursuing multiple regulatory pathways, including an official appeal process that typically takes around 60 days. HeartBeam believes that modifications to the device's proposed labeling can resolve outstanding issues and is committed to working with the agency towards a constructive resolution. No grant or funding involving multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire  on Novem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL8YfztQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAT","BK4082"],"gpt_icon":0},{"id":"2586983392","title":"Heartbeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead Ecg Synthesis Software Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2586983392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586983392?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:32","pubTimestamp":1764192720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA76G4TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAT","BK4082"],"gpt_icon":0},{"id":"2585128738","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2585128738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585128738?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:12","pubTimestamp":1763752356,"startTime":"0","endTime":"0","summary":"HeartBeam  shares sank 56% after the company reported Friday receiving a \"Not Substantially Equivalent\" letter from the US Food and Drug Administration regarding the 510 application for its 12-Lead Electrocardiogram Synthesis Software.More than 8.3 million shares of the company traded intraday compared with a daily average of about 88,000.Oracle  shares fell amid mounting concerns over risk related to its AI capital expenditure. The company's 5-year credit default swaps, which reflect the cost of protecting its debt, have surged past 110 basis points, the highest in three years, according to a report from FXStreet.Shares dropped 4.8% as intraday trading volume climbed to more than 31.8 million from a daily average of roughly 25.2 million.Geospace Technologies  reported a drop in fiscal Q4 sales and a narrower loss from a year earlier.Shares slumped 23% as intraday trading volume rose to over 662,000 from a daily average of about 212,000.Price: 0.76, Change: -0.92, Percent Change: -54.7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0949170772.SGD","IE00B5949003.HKD","LU0256863811.USD","LU1803068979.SGD","LU1489326972.SGD","LU1935042488.USD","LU1934455194.USD","BK4082","LU0198837287.USD","BEAT","IE00B7SZLL34.SGD","SG9999003800.SGD","LU2458330169.SGD","LU1035773651.USD","LU1989772840.SGD","LU2543165471.USD","IE00BMPRXQ63.HKD","LU2108987350.USD","LU1642822529.SGD","LU1429558221.USD","LU0965509101.SGD","LU1935042215.USD","LU0314106906.USD","IE00BMPRXN33.USD","LU1934455277.USD","IE00BN8TJ469.HKD","LU2357305700.SGD","LU0965509010.AUD","LU0081259029.USD","LU0444973449.USD","LU1201861249.SGD","LU1935043023.USD","LU0985489474.SGD","LU1989772923.USD","LU0417517546.SGD","LU0348723411.USD","GEOS","IE0009356076.USD","LU1435385759.SGD","LU1720051017.SGD","LU2326559502.SGD","LU2896262040.SGD","IE00B19Z3B42.SGD","LU0068578508.USD","ORCL","LU1720051108.HKD","LU2746668974.SGD","LU0965509283.SGD","LU0545039389.USD","LU1691799644.USD"],"gpt_icon":1},{"id":"2585401891","title":"Roth sees potential FDA clearance for HeartBeam despite letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2585401891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585401891?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:40","pubTimestamp":1763746818,"startTime":"0","endTime":"0","summary":"Roth Capital keeps a Buy rating on HeartBeam (BEAT) with a $4 price target after the company received a “not substantially equivalent” letter from ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roth-sees-potential-fda-clearance-for-heartbeam-despite-letter-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roth-sees-potential-fda-clearance-for-heartbeam-despite-letter-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BEAT"],"gpt_icon":0},{"id":"2585114034","title":"HeartBeam sinks after ‘Not Substantially Equivalent’ letter from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2585114034","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585114034?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746510,"startTime":"0","endTime":"0","summary":"HeartBeam (BEAT) disclosed earlier today that it received a “Not Substantially Equivalent” letter from the Food and Drug Administration related to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/heartbeam-sinks-after-not-substantially-equivalent-letter-from-fda-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/heartbeam-sinks-after-not-substantially-equivalent-letter-from-fda-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAT","BK4082"],"gpt_icon":0},{"id":"2585418241","title":"Heartbeam Inc - to Work With FDA to Resolve Nse Issue - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585418241","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585418241?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:49","pubTimestamp":1763736553,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0QF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAT","BK4082"],"gpt_icon":0},{"id":"2585141375","title":"HeartBeam Receives FDA NSE Letter for 12-Lead ECG Synthesis Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585141375?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:48","pubTimestamp":1763736504,"startTime":"0","endTime":"0","summary":"HeartBeam Inc. announced that it received a Not Substantially Equivalent  letter from the U.S. Food and Drug Administration  regarding its 510 application for its 12-Lead Electrocardiogram  Synthesis Software. The company stated it stands behind its clinical data and plans to work with the FDA to resolve the issue. Additionally, HeartBeam is considering launching its novel 3D ECG system, which previously received FDA 510 clearance in December 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLbb037d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BEAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://heartbeam.com","stockEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.5484},{"period":"3month","weight":0.4545},{"period":"6month","weight":0.9355},{"period":"1year","weight":0.1268},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.13264},{"month":2,"riseRate":0,"avgChangeRate":-0.16996},{"month":3,"riseRate":0.5,"avgChangeRate":0.051598},{"month":4,"riseRate":0,"avgChangeRate":-0.117197},{"month":5,"riseRate":0.75,"avgChangeRate":0.113183},{"month":6,"riseRate":0.25,"avgChangeRate":-0.106265},{"month":7,"riseRate":0.75,"avgChangeRate":0.0685},{"month":8,"riseRate":0.25,"avgChangeRate":-0.077406},{"month":9,"riseRate":0.75,"avgChangeRate":0.57126},{"month":10,"riseRate":0.5,"avgChangeRate":-0.101273},{"month":11,"riseRate":0.75,"avgChangeRate":0.033079},{"month":12,"riseRate":0.6,"avgChangeRate":0.498962}],"exchange":"NASDAQ","name":"Heartbeam Inc","nameEN":"Heartbeam Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Heartbeam Inc(BEAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Heartbeam Inc(BEAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Heartbeam Inc,BEAT,Heartbeam Inc股票,Heartbeam Inc股票老虎,Heartbeam Inc股票老虎国际,Heartbeam Inc行情,Heartbeam Inc股票行情,Heartbeam Inc股价,Heartbeam Inc股市,Heartbeam Inc股票价格,Heartbeam Inc股票交易,Heartbeam Inc股票购买,Heartbeam Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Heartbeam Inc(BEAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Heartbeam Inc(BEAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction